Anavex Life Sciences (Anavex Life Sciences) EPS (Diluted) : $-0.55 (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences EPS (Diluted)?

Anavex Life Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.11. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55.

Anavex Life Sciences's EPS (Basic) for the three months ended in Dec. 2023 was $-0.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55.

Anavex Life Sciences's EPS without NRI for the three months ended in Dec. 2023 was $-0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55.

During the past 3 years, the average EPS without NRIGrowth Rate was -9.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -8.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Anavex Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 35.30% per year. The lowest was -257.60% per year. And the median was -5.25% per year.

Anavex Life Sciences EPS (Diluted) Historical Data

The historical data trend for Anavex Life Sciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences EPS (Diluted) Chart

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EPS (Diluted)

Get a 7-Day Free Trial

-0.54

-0.45

-0.54

-0.62

-0.60

Anavex Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-0.17	-0.17	-0.14	-0.13	-0.11

Competitive Comparison of Anavex Life Sciences's EPS (Diluted)

For the Biotechnology subindustry, Anavex Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's PE Ratio falls into.

Anavex Life Sciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Anavex Life Sciences's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-47.505	-	0)	/	79.788
	=	-0.60

Anavex Life Sciences's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.622	-	0)	/	82.078
	=	-0.11

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55

Anavex Life Sciences (NAS:AVXL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Anavex Life Sciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences (Anavex Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

12X1:Germany 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Executives

Christopher U Missling	director, officer: President, CEO, CFO, Treasurer, other: Secretary	61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos	10 percent owner	14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma	director	445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Donhauser Peter D.o.	director	REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Sandra Boenisch	officer: PFO & Treasurer	51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden	director	PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Steffen Thomas	director	FALLMERAYER STR. 19, MUNICH 2M 80796
Bernd Metzner	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh	director, officer: Executive Director
John Robert Chisholm	director	16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry	director	1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley	director	14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach	director, officer: President CEO CFO	4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers	director	27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052